688176 亚虹医药
已收盘 03-04 15:00:01
资讯
新帖
简况
3月4日亚虹医药（688176）龙虎榜数据：北向资金净买入356.2万元
证券之星 · 17:16
3月4日亚虹医药（688176）龙虎榜数据：北向资金净买入356.2万元
创新药概念局部回暖 亚虹医药20%涨停
每日经济新闻 · 13:44
创新药概念局部回暖 亚虹医药20%涨停
异动快报：亚虹医药-U（688176）3月4日13点33分触及涨停板
证券之星 · 13:35
异动快报：亚虹医药-U（688176）3月4日13点33分触及涨停板
亚虹医药(688176.SH)：希维她®获得国家药品监督管理局批准上市
智通财经 · 03-03 17:49
亚虹医药(688176.SH)：希维她®获得国家药品监督管理局批准上市
每周股票复盘：亚虹医药（688176）2025年净亏损4.193亿元
证券之星 · 03-01
每周股票复盘：亚虹医药（688176）2025年净亏损4.193亿元
亚虹医药营收增长难破亏损困局，多条管线迎突破盈利拐点却未明
市场资讯 · 02-24
亚虹医药营收增长难破亏损困局，多条管线迎突破盈利拐点却未明
亚虹医药营收增长难破亏损困局，多条管线迎突破盈利拐点却未明
证券之星 · 02-14
亚虹医药营收增长难破亏损困局，多条管线迎突破盈利拐点却未明
股市必读：亚虹医药（688176）预计2025年全年营业收入2.42亿元至2.91亿元
证券之星 · 02-02
股市必读：亚虹医药（688176）预计2025年全年营业收入2.42亿元至2.91亿元
亚虹医药（688176）披露2025年年度业绩预亏公告，1月30日股价下跌3.27%
证券之星 · 01-30
亚虹医药（688176）披露2025年年度业绩预亏公告，1月30日股价下跌3.27%
1月29日亚虹医药跌7.91%，中航优选领航混合发起A基金重仓该股
证券之星 · 01-29
1月29日亚虹医药跌7.91%，中航优选领航混合发起A基金重仓该股
每周股票复盘：亚虹医药（688176）PL-2501预计2026年中报IND
证券之星 · 01-25
每周股票复盘：亚虹医药（688176）PL-2501预计2026年中报IND
亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可
智通财经 · 01-22
亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可
【机构调研记录】建信基金调研爱迪特、亚虹医药
证券之星 · 01-22
【机构调研记录】建信基金调研爱迪特、亚虹医药
每周股票复盘：亚虹医药（688176）拟用不超12亿闲置募资做现金管理
证券之星 · 01-18
每周股票复盘：亚虹医药（688176）拟用不超12亿闲置募资做现金管理
亚虹医药（688176）披露使用部分暂时闲置募集资金进行现金管理，1月16日股价上涨1.75%
证券之星 · 01-16
亚虹医药（688176）披露使用部分暂时闲置募集资金进行现金管理，1月16日股价上涨1.75%
每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组
证券之星 · 01-11
每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组
亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%
证券之星 · 01-08
亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%
亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组
智通财经 · 01-08
亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组
每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效
证券之星 · 01-02
每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效
股市必读：亚虹医药（688176）12月29日披露最新机构调研信息
证券之星 · 2025-12-30
股市必读：亚虹医药（688176）12月29日披露最新机构调研信息
加载更多
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是APL-1702、海克威、APL-1202/APL-1501、APL-2302、APL-2501、APL-2304、APL-1401、APL-2301、马来酸奈拉替尼片（商品名：欧优比）、培唑帕尼片（商品名：迪派特）、甲磺酸艾立布林注射液（商品名：欧纳琳）。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":13.67,"timestamp":1772607601000,"preClose":11.39,"halted":0,"volume":41676819,"delay":0,"changeRate":0.2002,"floatShares":436000000,"shares":571000000,"eps":-0.6341,"marketStatus":"已收盘","change":2.28,"latestTime":"03-04 15:00:01","open":12.1,"high":13.67,"low":12.01,"amount":542000000,"amplitude":0.1457,"askPrice":0,"askSize":0,"bidPrice":13.67,"bidSize":23885,"shortable":0,"etf":0,"ttmEps":-0.6341,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772674200000},"marketStatusCode":5,"adr":0,"adjPreClose":11.39,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772587800000,1772595000000],[1772600400000,1772607600000]],"highLimit":12.53,"lowLimit":10.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":571170486,"isCdr":false,"pbRate":4.48,"roa":"--","roe":"--","epsLYR":-0.68,"committee":0,"marketValue":7808000000,"turnoverRate":0.0957,"status":0,"afterMarket":{"amount":0,"volume":0,"close":13.67,"buyVolume":20700,"sellVolume":0,"time":1772609637558,"indexStatus":"已收盘 03-04 15:30:00","preClose":11.39},"floatMarketCap":5956000000},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2616533053","title":"3月4日亚虹医药（688176）龙虎榜数据：北向资金净买入356.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616533053?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:16","pubTimestamp":1772615769,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年3月4日公布的交易公开信息显示，亚虹医药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年3月4日收盘，亚虹医药报收于13.67元，上涨20.02%，涨停，换手率9.57%，成交量41.68万手，成交额5.42亿元。从龙虎榜公布的当日买卖数据来看，北向资金合计净买入356.2万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400030111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2616586662","title":"创新药概念局部回暖 亚虹医药20%涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2616586662","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616586662?lang=zh_cn&edition=full","pubTime":"2026-03-04 13:44","pubTimestamp":1772603040,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月4日，午后创新药概念局部回暖，亚虹医药20%涨停，艾力斯涨超10%，润都股份、欧林生物、凯莱英、首药控股等跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-04/doc-inhpvaym0142242.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-04/doc-inhpvaym0142242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","688176","BK0239","BK1161"],"gpt_icon":0},{"id":"2616585930","title":"异动快报：亚虹医药-U（688176）3月4日13点33分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2616585930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616585930?lang=zh_cn&edition=full","pubTime":"2026-03-04 13:35","pubTimestamp":1772602524,"startTime":"0","endTime":"0","summary":"证券之星3月4日盘中消息，13点33分亚虹医药-U（688176）触及涨停板。其所属行业化学制药目前下跌。领涨股为亚虹医药。该股为创新药，医药概念热股。3月3日的资金流向数据方面，主力资金净流出2230.31万元，占总成交额15.09%，游资资金净流入932.27万元，占总成交额6.31%，散户资金净流入1298.05万元，占总成交额8.79%。近5日资金流向一览见下表：亚虹医药-U主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400020511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2616969343","title":"亚虹医药(688176.SH)：希维她®获得国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2616969343","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616969343?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:49","pubTimestamp":1772531354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药 发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，批准公司APL-1702上市，用于治疗18岁及以上经组织学证实为子宫颈上皮内瘤变2级患者，排除子宫颈浸润癌和子宫颈原位腺癌。根据公开资料查询，希维她作为一款集药物和器械为一体的光动力产品，是全球首个针对该患者人群获批上市的非手术的无创治疗产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚虹医药(688176.SH)：希维她®获得国家药品监督管理局批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2616843934","title":"每周股票复盘：亚虹医药（688176）2025年净亏损4.193亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843934?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:03","pubTimestamp":1772301795,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，亚虹医药报收于12.15元，较上周的11.98元上涨1.42%。本周，亚虹医药2月27日盘中最高价报12.28元。本周关注点来自业绩披露要点：亚虹医药2025年归属净利润亏损4.193亿元，同比扩大。公司公告汇总江苏亚虹医药科技股份有限公司发布2025年度业绩快报，报告期内实现营业总收入27,712.15万元，同比增长37.49%；归属于母公司所有者的净利润为-41,934.08万元，净亏损同比扩大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2613795833","title":"亚虹医药营收增长难破亏损困局，多条管线迎突破盈利拐点却未明","url":"https://stock-news.laohu8.com/highlight/detail?id=2613795833","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613795833?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:55","pubTimestamp":1771919700,"startTime":"0","endTime":"0","summary":" 聚焦泌尿生殖系统肿瘤及女性健康领域的亚虹医药，凭借迪派特、欧优比两款商业化产品实现营收增长，2025年营收预计同比最高增超44%，且核心在研产品APL-1702等管线接连迎来研发突破。 证券之星注意到，受行业特性及前期研发投入影响，亚虹医药自上市以来持续亏损。整体来看，亚虹医药多条在研管线的研发仍在推进，但其盈利拐点的到来仍需等待。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-02-24/doc-inhnxhnk8782952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688176"],"gpt_icon":0},{"id":"2611011507","title":"亚虹医药营收增长难破亏损困局，多条管线迎突破盈利拐点却未明","url":"https://stock-news.laohu8.com/highlight/detail?id=2611011507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611011507?lang=zh_cn&edition=full","pubTime":"2026-02-14 15:18","pubTimestamp":1771053517,"startTime":"0","endTime":"0","summary":"亚虹医药同时预计，2025年归属净利润亏损区间为3.78亿元到4.53亿元，扣非后净利润亏损3.96亿元至4.76亿元，亏损局面仍将延续。亚虹医药称，将加快推进其上市审评审批工作，以期尽快获得上市批准。整体来看，亚虹医药多条在研管线的研发仍在推进，但其盈利拐点的到来仍需等待。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026021400008705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"gpt_icon":0},{"id":"2608326885","title":"股市必读：亚虹医药（688176）预计2025年全年营业收入2.42亿元至2.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608326885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608326885?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:09","pubTimestamp":1769965751,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，亚虹医药报收于12.72元，下跌3.27%，换手率4.31%，成交量18.76万手，成交额2.41亿元。来自公司公告汇总：亚虹医药预计2025年度归属净利润亏损3.78亿元至4.53亿元，较上年同期亏损同比增加18.00%到减少1.67%。业绩披露要点业绩预告亚虹医药发布业绩预告，预计2025年全年营业收入2.42亿元至2.91亿元；扣非后净利润亏损3.96亿元至4.76亿元；归属净利润亏损3.78亿元至4.53亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"gpt_icon":0},{"id":"2607704941","title":"亚虹医药（688176）披露2025年年度业绩预亏公告，1月30日股价下跌3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704941","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704941?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:15","pubTimestamp":1769782551,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，亚虹医药报收于12.72元，较前一交易日下跌3.27%，最新总市值为72.65亿元。该股当日开盘13.15元，最高13.35元，最低12.48元，成交额达2.41亿元，换手率为4.31%。近日，江苏亚虹医药科技股份有限公司发布2025年年度业绩预亏公告。2025年度营业收入预计为24,248.13万元到29,097.76万元，同比增长20.30%到44.36%；研发费用预计为25,366.63万元到30,439.95万元，同比减少2.41%到18.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2607704576","title":"1月29日亚虹医药跌7.91%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704576","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704576?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:38","pubTimestamp":1769675900,"startTime":"0","endTime":"0","summary":"证券之星消息，1月29日亚虹医药跌7.91%，收盘报13.15元，换手率6.32%，成交量27.52万手，成交额3.74亿元。重仓亚虹医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.47亿元，最新净值1.7236，较上一交易日下跌0.35%，近一年上涨70.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900027043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2606232644","title":"每周股票复盘：亚虹医药（688176）PL-2501预计2026年中报IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232644","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232644?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:37","pubTimestamp":1769279829,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，亚虹医药报收于14.21元，较上周的13.39元上涨6.12%。本周，亚虹医药1月22日盘中最高价报14.54元，股价触及近一年最高点。本周关注点来自机构调研要点：PL-2501预计在2026年中期递交IND。来自公司公告汇总：APL-2401获澳大利亚Ⅰ期临床试验许可。PL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验已完成首例受试者入组。目前已完成人源化实验、体内外药效研究及前期安全性验证，预计2026年中期递交IND。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2605461931","title":"亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2605461931","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605461931?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:27","pubTimestamp":1769074044,"startTime":"0","endTime":"0","summary":"按照澳大利亚药品注册相关法律法规，公司已获得该产品I期临床试验许可。此前APL-2401临床试验申请已获得国家药品监督管理局批准，公司将积极推进该产品的国际多中心临床研究。临床前实验表明APL-2401在多种FGFR2/3基因突变，扩增或过表达模型中展现出优异的疗效和更宽的安全窗。与现有同类产品相比，APL-2401在活性、选择性、安全性和成药性方面均显示出潜在的同类最佳优势，有望成为FGFR2/3靶向治疗领域的重磅产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2605117434","title":"【机构调研记录】建信基金调研爱迪特、亚虹医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605117434?lang=zh_cn&edition=full","pubTime":"2026-01-22 08:12","pubTimestamp":1769040747,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月21日披露的机构调研信息，建信基金近期对2家上市公司进行了调研，相关名单如下：1）爱迪特 调研纪要：公司2025年上半年海外市场实现收入3.27亿元，同比增长34%，主要得益于大客户战略推进、全球化运营体系完善、产品线拓展及品牌建设。公司通过研发创新、生产降本和供应链协同提升毛利率。旗下最近一年表现最佳的公募基金产品为建信电子行业股票A，最新单位净值为2.18，近一年增长72.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200005640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301580","688176","BK0251","BK0239"],"gpt_icon":0},{"id":"2604895925","title":"每周股票复盘：亚虹医药（688176）拟用不超12亿闲置募资做现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604895925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604895925?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:37","pubTimestamp":1768678627,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，亚虹医药报收于13.39元，较上周的11.99元上涨11.68%。本周，亚虹医药1月15日盘中最高价报13.57元，股价触及近一年最高点。本周关注点公司公告汇总：亚虹医药拟使用最高不超过12亿元闲置募集资金进行现金管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2603944469","title":"亚虹医药（688176）披露使用部分暂时闲置募集资金进行现金管理，1月16日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603944469","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603944469?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:39","pubTimestamp":1768574352,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，亚虹医药报收于13.39元，较前一交易日上涨1.75%，最新总市值为76.48亿元。该股当日开盘13.03元，最高13.54元，最低13.03元，成交额达2.51亿元，换手率为4.33%。亚虹医药近日发布公告称，公司于2026年1月16日召开董事会，审议通过了关于使用部分暂时闲置募集资金进行现金管理的议案。该事项已获董事会批准，保荐人无异议，无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2602398635","title":"每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398635?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:28","pubTimestamp":1768076889,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，亚虹医药报收于11.99元，较上周的11.51元上涨4.17%。本周，亚虹医药1月9日盘中最高价报12.24元。亚虹医药当前最新总市值68.48亿元，在化学制药板块市值排名85/150，在两市A股市值排名2758/5182。公司公告汇总江苏亚虹医药科技股份有限公司自愿披露关于APL-2401完成I期临床试验首例受试者入组公告。该药物已纳入国家药监局“30日通道”，并在获批后15个工作日内实现首例给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2601845398","title":"亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601845398","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601845398?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:24","pubTimestamp":1767882261,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，亚虹医药报收于11.78元，较前一交易日上涨1.55%，最新总市值为67.28亿元。该股当日开盘11.6元，最高11.91元，最低11.52元，成交额达1.42亿元，换手率为2.77%。公司近日发布公告称，其自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验已完成首例受试者入组。APL-2401为高选择性FGFR2/3双靶点小分子抑制剂，临床前研究显示其在多种FGFR2/3异常模型中具有优异疗效和更宽安全窗。目前该事项对公司近期业绩无重大影响，后续进展存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2601594773","title":"亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2601594773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601594773?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:09","pubTimestamp":1767859754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，公司自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验完成首例受试者入组。APL-2401是公司自主研发的高选择性成纤维生长因子受体2/3(FGFR2/3)双靶点小分子抑制剂，有望为晚期实体瘤(例如：尿路上皮癌、胆管癌、子宫内膜癌、胃癌、乳腺癌、卵巢癌、非小细胞肺癌和其他特定实体瘤)患者提供一种新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2600003991","title":"每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2600003991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600003991?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:11","pubTimestamp":1767298269,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，亚虹医药报收于11.06元，较上周的11.36元下跌2.64%。本周，亚虹医药12月22日盘中最高价报11.62元。PL-2401为全球同步研发的1类创新药，已纳入国家药监局“30日通道”，仅用22个工作日获得临床试验批准，系全国首批获批项目之一。相比现有产品，PL-2401显著降低FGFR1和FGFR4相关毒副作用，临床前模型中展现宽安全窗和优异疗效，具潜在同类最佳优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2595349577","title":"股市必读：亚虹医药（688176）12月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2595349577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595349577?lang=zh_cn&edition=full","pubTime":"2025-12-30 01:00","pubTimestamp":1767027645,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，亚虹医药报收于11.57元，上涨4.61%，换手率3.67%，成交量15.98万手，成交额1.83亿元。来自机构调研要点：PL-2401成为全国首批通过“30日通道”获批的创新药项目之一，仅用22个工作日获临床试验批准。PL-2401为全球同步研发的1类创新药，已获国家药监局批准开展在FGFR2/3驱动的晚期实体瘤患者中的I期临床试验，仅用22个工作日完成审批，成为全国首批纳入“30日通道”的项目之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000000567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772621862284,"stockEarnings":[{"period":"1week","weight":-0.0306},{"period":"1month","weight":-0.1046},{"period":"3month","weight":0.1646},{"period":"6month","weight":-0.0445},{"period":"1year","weight":0.3993},{"period":"ytd","weight":-0.0104}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0631},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.2429},{"period":"ytd","weight":0.0388}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25192人(较上一季度减少1.06%)","perCapita":"17294股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57117万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是APL-1702、海克威、APL-1202/APL-1501、APL-2302、APL-2501、APL-2304、APL-1401、APL-2301、马来酸奈拉替尼片（商品名：欧优比）、培唑帕尼片（商品名：迪派特）、甲磺酸艾立布林注射液（商品名：欧纳琳）。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}